use of mechanical ventilation with positive end-expiratory pressure.The use of surfactant in children with ARDS increased oxygenation and allowed reduction of ventilation parameters,and decreased time spent on ventilation and in the ICU;the decrease in mortality has not been proved.It seems that the ...
The acute respiratory distress syndrome (ARDS) characterizes different states of acute impairment of pulmonary gas exchange. Underlying noxious events may directly affect lung parenchyma from the alveolar side (e.g. gastric acid aspiration), or — more classically — the lung vasculature may be the ...
Considerations for the use and study of exogenous surfactant in respiratory disease from COVID-19ARDSsurfactantCOVID-19Exogenous surfactant therapy has been widely studied in acute respiratory distress syndrome (ARDS) but has failed to show mortality benefit in several trials. The COVID-19 pandemic ...
The search for therapeutic agents to improve the clinical outcome in adult patients with the acute respiratory distress syndrome (ARDS) has focused on early intervention. A variety of approaches have been attempted using methods that modulate the components of the systemic inflammatory response, but no...
Surfactantsare a large group of surface-active materials that find use in versatile applications in everyday life. They can be found in household and personal care products, as well as drug dosage forms. Due to their amphipathic properties, within these formulations surfactants may serveas detergent...
Modified natural surfactant is an effective treatment option in children with ARDS for improving gas exchange, decreasing the use of ventilatory support and increasing survival time. Introduction Acute respiratory distress syndrome (ARDS) is an important clinical condition in paediatric intensive care ...
The feasibility and safety of surfactant delivery in COVID-19 ARDS patients have not been established. Methods We performed retrospective analyses of data from patients receiving off-label use of exogenous natural surfactant during the COVID-19 pandemic. Seven COVID-19 PCR positive ARDS patients ...
EXOGENOUS SURFACTANT SUPPLEMENTATION Giuseppe A. Marraro, MD Director of Anaesthesia and Intensive Care Department & Paediatric Intensive Care Unit Fatebenefratelli and Ophthalmiatric Hospital Milan, Italy *** Introduction The utility of surfactant treatment was demonstrated in premature animal models by En...
use of INO significantly reduced the need for extracorporeal membrane oxygenation(ECMO).7 In the clinical trials for adult patients with ARDS, INO failed to show benefits in mortality reduction although improvement of oxygenation was observed.8-11 To test surfactant in term neonates with severe ...
Revak SD, Merritt TA, Degryse E, Stefani L, Courtney M, Hallman M, Cochrane CG (1988) Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity. J Clin Invest 81: 826–833. PubMed CAS Google Scholar Whitsett JA, Ohning BL, Ross G, ...